CA Patent

CA2716578A1 — Use of rifaximin in subjects having diarrhea-predominant irritable bowel syndrome

Assigned to Salix Pharmaceuticals Inc · Expires 2009-09-03 · 17y expired

What this patent protects

The present invention provides new methods of treating bowel disease (BD) by increasing a durability of response; treating BD in males; treating BD in adolescent subjects; treating bloating due to BD in males; and methods of maintaining remission of BD.

USPTO Abstract

The present invention provides new methods of treating bowel disease (BD) by increasing a durability of response; treating BD in males; treating BD in adolescent subjects; treating bloating due to BD in males; and methods of maintaining remission of BD.

Drugs covered by this patent

Patent Metadata

Patent number
CA2716578A1
Jurisdiction
CA
Classification
—
Expires
2009-09-03
Drug substance claim
No
Drug product claim
No
Assignee
Salix Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.